Switzerland · Delayed Price · Currency is CHF Basilea Pharmaceutica AG Company Description
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections.
The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), and acute bacterial skin and skin structure infections (ABSSSI).
The company also has a clinical-stage pipeline of anti-infective assets that include fosmanogepix, a broad-spectrum antifungal in phase 3 development for invasive mold and yeast infections; ceftibuten-ledaborbactam, a phase 3–ready oral antibiotic for the treatment of complicated urinary tract infections (cUTI); BAL2062, a candidate for invasive aspergillosis currently advancing toward phase 2 clinical development; and BAL2420, a preclinical-stage antibiotic targeting severe Enterobacteriaceae infections.
Basilea Pharmaceutica AG was founded in 2000 and is headquartered in Allschwil, Switzerland.
| Country | Switzerland |
| Founded | 2000 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 164 |
| CEO | David Veitch |
Contact Details
Address: Hegenheimermattweg 167b Allschwil, 4123 Switzerland | |
| Phone | 41 61 606 11 11 |
| Website | basilea.com |
Stock Details
| Ticker Symbol | BSLN |
| Exchange | SIX Swiss Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CHF |
| ISIN Number | CH0011432447 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| David Veitch | Chief Executive Officer |
| Adesh Kaul | Chief Financial Officer |
| Dr. Gerrit Hauck Ph.D. | Chief Technology Officer |
| Dr. Laurenz Kellenberger Ph.D. | Chief Scientific Officer |
| Dr. Marc Engelhardt M.D. | Chief Medical Officer |
| Dr. Peer Nils Schroder Ph.D. | Head of Corporate Communications and Investor Relations |
| Damian Heller | General Counsel and Corporate Secretary |
| Andreas Kumin | Head of Corporate Development |
| Ursula Eberhardt | Head of Global Human Resources |
| Mark Jones Ph.D. | Head of Global Affairs |